Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?

BMC Gastroenterol. 2005 Sep 19:5:30. doi: 10.1186/1471-230X-5-30.

Abstract

Background: Our aim was to determinate bone mineral density (BMD), levels of biochemical markers and cytokines in children with chronic hepatitis B treated with interferon (IFN)-alpha and to investigate effect of IFN-alpha therapy on these variables. To the best of our knowledge, this is first study carried out about BMD and cytokine levels in pediatric patients with chronic hepatitis B treated with IFN-alpha.

Methods: BMD, levels of parathyroid hormone (PTH), osteocalcin, C-terminal cross-linking telopeptide of type I collagen (CTX), calcium, alkaline phosphates (ALP), cytokines as TNF-alpha, interleukin (IL)-1beta, IL-2r, IL-6, and IL-8 were studied in 54 children with chronic hepatitis B (4-15 years old) treated with interferon alone (n = 19) or in combination with lamivudine (n = 35) for six months and as controls in 50 age-matched healthy children.

Results: There was no significant difference in respect to serum IL-1beta, TNF-alpha and osteocalcin levels while serum IL-2r (p = 0.002), IL-6 (p = 0.001), IL-8 (p = 0.013), PTH (p = 0.029), and CTX (p = 0.021) levels were higher in children with chronic hepatitis B than in healthy controls. BMD of femur neck (p = 0.012) and trochanter (p = 0.046) in patients were higher than in healthy controls. There was a statistically significant correlation between serum IL-1beta and osteocalcin (r = -0.355, p < 0.01); between serum IL-8 and CTX levels (r = 0.372, p = 0.01), and ALP (r = 0.361, p = 0.01); between serum ALP and femur neck BMD (r = 0.303, p = 0.05), and trochanter BMD (r = 0.365, p = 0.01); between spine BMD and IL-2R (r = -0.330, p < 0.05).

Conclusion: In conclusion, our study suggest that BMD of femur, serum IL-2r, IL-6, IL-8, PTH, and CTX levels were higher in children with chronic hepatitis B treated with IFN-alpha alone or combination with lamivudine than in healthy children. High femur BMD measurements found in patients may suggest that IFN-alpha therapy in children with chronic hepatitis B could contribute indirectly to prevent from hip osteoporosis. Additionally, further investigations on effects of IFN-alpha for bone structure in children should be performed in the future.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Antiviral Agents / therapeutic use*
  • Bone Density / drug effects*
  • Child
  • Child, Preschool
  • Collagen / blood
  • Collagen Type I
  • Cytokines / blood*
  • Drug Therapy, Combination
  • Female
  • Femur / metabolism
  • Hepatitis B, Chronic / blood
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / metabolism*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Interleukins / blood
  • Lamivudine / therapeutic use
  • Male
  • Osteoporosis / prevention & control*
  • Parathyroid Hormone / blood
  • Peptides / blood
  • Receptors, Interleukin-2 / blood
  • Recombinant Proteins
  • Reverse Transcriptase Inhibitors / therapeutic use

Substances

  • Antiviral Agents
  • Collagen Type I
  • Cytokines
  • Interferon alpha-2
  • Interferon-alpha
  • Interleukins
  • Parathyroid Hormone
  • Peptides
  • Receptors, Interleukin-2
  • Recombinant Proteins
  • Reverse Transcriptase Inhibitors
  • collagen type I trimeric cross-linked peptide
  • Lamivudine
  • Collagen